GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention
Authors
Furman, Mark I.Krueger, Lori A.
Linden, Matthew Dean
Fox, Marsha L.
Ball, Steven P.
Barnard, Marc R.
Frelinger, Andrew L. III
Michelson, Alan D.
UMass Chan Affiliations
Department of PediatricsDocument Type
Journal ArticlePublication Date
2005-02-01Keywords
Acute DiseaseAged
Angioplasty, Balloon, Coronary
Antibodies, Monoclonal
Blood Platelets
CD40 Ligand
Coronary Disease
Female
Humans
Immunoglobulin Fab Fragments
Inflammation
Leukocytes
Male
Middle Aged
Platelet Adhesiveness
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Ticlopidine
Hematology
Oncology
Pediatrics
Metadata
Show full item recordAbstract
OBJECTIVE: To investigate the effects of abciximab, eptifibatide and no GPIIb-IIIa antagonist (control) on soluble CD40 ligand (sCD40L) and the formation of leukocyte-platelet aggregates (LPA) in 98 ACS patients undergoing percutaneus coronary intervention (PCI). BACKGROUND: sCD40L and LPA are increased in patients with ACS. METHODS: sCD40L was measured by enzyme-linked immunosorbent assay (ELISA) and LPA by whole blood flow cytometry. RESULTS: There were no baseline differences between the three groups in sCD40L and LPA. At the end of PCI, sCD40L was unchanged in the controls, decreased by 30% (P andlt; 0.001) in the abciximab group and by 11% (P andlt; 0.02) in the eptifibatide group. Eighteen to 24 h after PCI, sCD40L was unchanged in the controls, reduced 30% (P andlt; 0.001) in the abciximab-treated group and 9% (P andlt; 0.01) in the eptifibatide-treated group. At the end of PCI, circulating monocyte-platelet aggregates (MPA) were reduced by 12% (P = NS) in the abciximab-treated group, 13% in the eptifibatide-treated group (P = NS), but slightly increased in the controls (P = NS). Eighteen to 24 h after PCI, MPA were reduced by 41% (P andlt; 0.001) compared to baseline in the abciximab-treated group, by 23% (P = NS) in the eptifibatide-treated group, and 15% (P = NS) in the controls. In contrast to control patients presenting while on clopidogrel, control patients presenting not on clopidogrel demonstrated a reduction in sCD40L and LPA 18-24 h post-PCI (P = NS). At low receptor occupancy, GPIIb-IIIa antagonists did not augment the release of sCD40L or the number of circulating LPA. CONCLUSIONS: GPIIb-IIIa antagonists reduce circulating sCD40L and LPA formation in patients with ACS undergoing PCI. At low receptor occupancy, GPIIb-IIIa antagonists do not activate platelets.Source
J Thromb Haemost. 2005 Feb;3(2):312-20. doi 10.1111/j.1538-7836.2005.01124.xDOI
10.1111/j.1538-7836.2005.01124.xPermanent Link to this Item
http://hdl.handle.net/20.500.14038/43378PubMed ID
15670038Related Resources
Link to article in PubMedae974a485f413a2113503eed53cd6c53
10.1111/j.1538-7836.2005.01124.x